Prothena Leadership Transition Amid Neurodegenerative R&D Push
Company Announcements

Prothena Leadership Transition Amid Neurodegenerative R&D Push

The latest update is out from Prothena ( (PRTA) ).

Prothena Corporation has announced a strategic leadership change as Dr. Hideki Garren steps down as Chief Medical Officer to join a major pharmaceutical company. Succeeding him is Dr. Chad Swanson, newly appointed Chief Development Officer, who brings over two decades of neuropharmacology experience to the role. This move is set against the backdrop of Prothena’s advancement in developing treatments for neurodegenerative and rare diseases, highlighting the company’s commitment to innovation in protein dysregulation and its robust R&D pipeline.

For a thorough assessment of PRTA stock, go to TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistPRTA Earnings this Week: How Will it Perform?
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyProthena price target lowered to $31 from $33 at BofA
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App